Contrast-enhanced MR angiography of the run-off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine

Journal of Magnetic Resonance Imaging

Volumn 17, Issue 6, 2003, Pages 694-702

  Knopp, Michael V ^a,b   Giesel, Frederik L ^b   Von Tengg Kobligk, Hendrik ^a,b   Radeleff, Jannis ^b   Requardt, Martin ^c   Kirchin, Miles A ^d   Hentrich, Hans Rainer ^e  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c SIEMENS AG   (Germany)

^d Bracco Imaging SpA   (Italy)

^e ALTANA PHARMA AG   (Germany)

Author keywords

Arteries; Comparative studies; Contrast media; Extremities; Gadobenate dimeglumine; Magnetic resonance (MR) vascular studies

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE;

ABDOMEN; ADULT; ARTICLE; BLOOD VESSEL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTRAST NOISE RATIO; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMAGE QUALITY; LEG BLOOD VESSEL; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NORMAL HUMAN; PELVIS; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGNAL DETECTION; SIGNAL NOISE RATIO; THREE DIMENSIONAL IMAGING;

ADULT; ANALYSIS OF VARIANCE; AORTA, ABDOMINAL; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LEG; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PELVIS; POPLITEAL ARTERY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0038460329     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10313     Document Type: Article

References (31)

1. Shetty AN, Bis KG, Vrachliotis TG, et al. Contrast-enhanced 3D MRA with centric ordering in k space: a preliminary clinical experience in imaging the abdominal aorta and renal and peripheral arterial vasculature. J Magn Reson Imaging 1998;8:603-615.
2. Vosshenrich R, Kopka L, Castillo E, et al. Electrocardiograph-triggered two-dimensional time-of-flight versus optimized contrast-enhanced three-dimensional MR angiography of the peripheral arteries. Magn Reson Imaging 1998;16:887-892.
3. Yamashita Y, Mitsuzaki K, Ogata I, et al. Three-dimensional high-resolution dynamic contrast-enhanced MR angiography of the pelvis and lower extremities with use of a phased array coil and subtraction: diagnostic accuracy. J Magn Reson Imaging 1998;8: 1066-1072.
4. Ho KY, Leiner T, van Engelshoven JM, MR angiography of run-off vessels. Eur Radiol 1999;9:1285-1289.
5. Ruehm SG, Hany TF, Pfammatter T, et al. Pelvic and lower extremity arterial imaging: diagnostic performance of three-dimensional contrast-enhanced MR angiography. AJR Am J Roentgenol 2000; 174:1127-1135.
6. Ruehm SG, Nanz D, Baumann A, Schmid M. Debatin JF. 3D contrast-enhanced MR angiography of the run-off vessels: value of image subtraction. J Magn Reson Imaging 2001;13:402-411.
7. Koelemay MJW, Lijmer JG, Stoker J, Legemate DA, Bossuyt PMM. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA 2001;285:1338-1345.
8. Ho KY, de Haan MW, Oei TK, et al. MR angiography of the iliac and upper femoral arteries using four different inflow techniques. AJR Am J Roentgenol 1997;169:45-53.
9. Wasser MN. Magnetic resonance angiography of peripheral vascular disease. J Comput Assist Tomogr 1999;23(Suppl 1):S129-S133.
10. Quinn SF, Sheley RC, Semonsen KG, et al. Aortic and lower-extremity arterial disease: evaluation with MR angiography versus conventional angiography. Radiology 1998;206:693-701.
11. Velazquez OC, Baum RA, Carpenter JP. Magnetic resonance angiography of lower-extremity arterial disease. Surg Clin North Am 1998;78:519-537.
12. Winterer JT, Laubenberger J, Scheffler K, et al. Contrast-enhanced subtraction MR angiography in occlusive disease of the pelvic and lower limb arteries: results of a prospective intraindividual comparative study with digital subtraction angiography in 76 patients. J Comput Assist Tomogr 1999;23:583-589.
13. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. AJR Am J Roentgenol 2000;174:171-179.
14. Ho KY, Leiner T, de Haan MW, et al. Peripheral vascular tree stenoses: evaluation with moving-bed infusion-tracking MR angiography. Acad Radiol 1998;206:683-692.
15. Foo TKF, Ho VB, Hood MN, Marcos HB, Hess SL, Choyke PL. High-spatial resolution multistation MR imaging of lower-extremity peripheral vasculature with segmented volume acquisition: feasibility study. Radiology 2001;219:835-841.
16. Boos M, Lentschig M, Scheffler K, et al. Contrast-enhanced magnetic resonance angiography of peripheral vessels. Different contrast agent applications and sequence strategies: a review. Invest Radiol 1998;33:538-546.
17. Wang Y, Winchester PA, Khilnani NM, et al. Contrast-enhanced peripheral MR angiography from the abdominal aorta to the pedal arteries: combined dynamic two-dimensional and bolus-chase three-dimensional acquisitions. Invest Radiol 2001;36:170-177.
18. Earls JP, Patel NH, Smith PA, et al. Gadolinium-enhanced three-dimensional MR angiography of the aorta and peripheral arteries: evaluation of a multistation examination using two gadopentetate dimeglumine infusions. AJR Am J Roentgenol 1998;171:599-604.
19. Westenberg JJ, Wasser MN, van der Geest RJ, et al. Gadolinium contrast-enhanced three-dimensional MRA of peripheral arteries with multiple bolus injection: scan optimization in vitro and in vivo. Int J Card Imaging 1999;15:161-173.
20. Knopp MV, von Tengg-Kobligk H, Floemer F, Schoenberg SO. Contrast agents for MRA: future directions. J Magn Reson Imaging 1999;10:314-316.
21. de Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(Suppl 1):S161-S168.
22. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
23. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809.
24. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol 2002;37:706-715.
25. Völk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology 2001;220:484-488.
26. Herborn C, Lauenstein T, Ruehm S, Bosk S, Debatin J, Goyen M. Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol 2003;38:27-33.
27. von Tengg-Kobligk H, Floemer F, Knopp MV. Multiphasic MR angiography as an intra-individual comparison between the contrast agents Gd-DTPA, Gd-BOPTA, and Gd-BT-DO3A [in German]. Radiologe, 2003;43:171-178.
28. Fellner F, Janka R, Fellner C, et al. Gd-BOPTA: "the MRA contrast agent of choice"? Rontgenpraxis 1999;52:51-58.
29. Ruehm SG, Goyen M, Barkhausen J, et al. Rapid magnetic resonance angiography for detection of atherosclerosis. Lancet 2001; 357:1086-1091.
30. Goyen M, Herborn CU, Lauenstein TC, et al. Optimization of contrast dosage for gadobenate dimeglumine-enhanced high-resolution whole body 3D MR Angiography. Invest Radiol 2002;37:263-268.
31. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol 1999;6:282-291.